208 related articles for article (PubMed ID: 17526546)
1. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
Carrera F; Disney A; Molina M
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
[TBL] [Abstract][Full Text] [Related]
2. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
3. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
[TBL] [Abstract][Full Text] [Related]
4. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
5. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
Benz R; Schmidt R; Kelly K; Wolfson M
Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
[TBL] [Abstract][Full Text] [Related]
7. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
11. Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients.
Portolés J; Krisper P; Choukroun G; de Francisco AL
Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii13-17. PubMed ID: 16079324
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V;
Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of anaemia treatment in children with chronic kidney disease].
Puretić Z
Acta Med Croatica; 2009 Sep; 63 Suppl 1():27-32. PubMed ID: 20235352
[TBL] [Abstract][Full Text] [Related]
14. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Holloway M
Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
[TBL] [Abstract][Full Text] [Related]
15. Optimizing anaemia management with subcutaneous administration of epoetin.
Besarab A
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
[TBL] [Abstract][Full Text] [Related]
16. Once weekly treatment with epoetin-beta.
Locatelli F
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
[TBL] [Abstract][Full Text] [Related]
17. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of darbepoetin alfa.
Macdougall IC; Padhi D; Jang G
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv2-iv9. PubMed ID: 17526547
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]